JP7712207B2 - 新規な癌抗原及び方法 - Google Patents

新規な癌抗原及び方法

Info

Publication number
JP7712207B2
JP7712207B2 JP2021546487A JP2021546487A JP7712207B2 JP 7712207 B2 JP7712207 B2 JP 7712207B2 JP 2021546487 A JP2021546487 A JP 2021546487A JP 2021546487 A JP2021546487 A JP 2021546487A JP 7712207 B2 JP7712207 B2 JP 7712207B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
antigen
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514116A (ja
JPWO2020079448A5 (enExample
Inventor
カシオティス ジョージ
ヤング ジョージ
アッティグ ジャン
スナイダース ブラム
パーキンス デイヴィッド
マリノ ファビオ
ターネット ニコラ
Original Assignee
ザ フランシス クリック インスティチュート リミティッド
エナラ バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ フランシス クリック インスティチュート リミティッド, エナラ バイオ リミテッド filed Critical ザ フランシス クリック インスティチュート リミティッド
Publication of JP2022514116A publication Critical patent/JP2022514116A/ja
Priority to JP2022173369A priority Critical patent/JP7762132B2/ja
Publication of JPWO2020079448A5 publication Critical patent/JPWO2020079448A5/ja
Priority to JP2024212437A priority patent/JP2025041678A/ja
Application granted granted Critical
Publication of JP7712207B2 publication Critical patent/JP7712207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021546487A 2018-10-19 2019-10-18 新規な癌抗原及び方法 Active JP7712207B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022173369A JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18201634.5 2018-10-19
EP18201634 2018-10-19
PCT/GB2019/052980 WO2020079448A1 (en) 2018-10-19 2019-10-18 Novel cancer antigens and methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022173369A Division JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Division JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Publications (3)

Publication Number Publication Date
JP2022514116A JP2022514116A (ja) 2022-02-09
JPWO2020079448A5 JPWO2020079448A5 (enExample) 2022-11-10
JP7712207B2 true JP7712207B2 (ja) 2025-07-23

Family

ID=64183836

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021546487A Active JP7712207B2 (ja) 2018-10-19 2019-10-18 新規な癌抗原及び方法
JP2022173369A Active JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Pending JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022173369A Active JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Pending JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Country Status (12)

Country Link
US (2) US12263216B2 (enExample)
EP (1) EP3866827A1 (enExample)
JP (3) JP7712207B2 (enExample)
KR (1) KR20210080372A (enExample)
CN (2) CN112867501B (enExample)
AU (1) AU2019360427A1 (enExample)
BR (1) BR112021006941A2 (enExample)
CA (1) CA3112427A1 (enExample)
EA (1) EA202191081A1 (enExample)
IL (1) IL282308A (enExample)
MX (1) MX2021004453A (enExample)
WO (1) WO2020079448A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3866827A1 (en) 2018-10-19 2021-08-25 The Francis Crick Institute Limited Novel cancer antigens and methods
JP2022539157A (ja) * 2019-06-28 2022-09-07 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
EP4136097A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083334A1 (en) 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
WO2001064835A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1303601A2 (en) 2000-04-06 2003-04-23 PHARMACIA & UPJOHN COMPANY G protein-coupled receptors
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2003304877A (ja) 2002-04-15 2003-10-28 Keio Gijuku ヒト色素細胞特異分子
AU2003298606A1 (en) 2002-10-25 2004-05-13 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
ATE538802T1 (de) 2005-03-30 2012-01-15 Viroxis Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
US20090181380A1 (en) 2005-12-19 2009-07-16 Abdelmajid Belouchi Genemap of the human genes associated with crohn's disease
EP2032162A2 (en) 2006-05-22 2009-03-11 Board of Regents, The University of Texas System Herv-k antigens, antibodies, and methods
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
WO2008118258A2 (en) 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
US8541553B2 (en) 2007-05-24 2013-09-24 Baxter Healthcare Sa Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
WO2009026116A2 (en) 2007-08-16 2009-02-26 Genizon Biosciences, Inc. Genemap of the human genes associated with longevity
WO2009039244A2 (en) 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US8323659B2 (en) 2008-09-18 2012-12-04 Keio University Method for diagnosing and/or treating tumor
JP2014525269A (ja) 2011-08-30 2014-09-29 ディーシービー−ユーエスエー エルエルシー 卵巣新生物に対する易罹患性及び／又は卵巣がんの予後若しくは悪性度を予測する方法
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
FR2984362B1 (fr) 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
WO2014004385A2 (en) 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
EP3230473B1 (en) 2014-12-08 2020-04-29 The Regents Of The University Of Michigan Non-coding rnas and uses thereof
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
JP2019520038A (ja) 2016-04-21 2019-07-18 イマティクス バイオテクノロジーズ ゲーエムベーハー 黒色腫およびその他のがんに対する免疫療法
AU2017397458B2 (en) 2017-02-01 2025-07-10 Modernatx, Inc. RNA cancer vaccines
EP3866827A1 (en) 2018-10-19 2021-08-25 The Francis Crick Institute Limited Novel cancer antigens and methods
JP2022539157A (ja) 2019-06-28 2022-09-07 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法
CA3141229A1 (en) 2019-06-28 2020-12-30 The Francis Crick Institute Limited Novel cancer antigens and methods
CN114174323B (zh) 2019-07-05 2025-01-07 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法
JP7751817B2 (ja) 2019-07-05 2025-10-09 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083334A1 (en) 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUMER, J. et al.，Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses，Cancer Research，2006年02月01日，Vol. 66, No. 3，P. 1658-1663
MULLINS, C. S. et al.，Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes，Cancer Immunology, Immunotherapy，2011年12月21日，Vol. 61, No. 7，P. 1093-1100
SCHIAVETTI, F. et al.，A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes，Cancer Research，2002年10月01日，Vol. 62, No. 19，P. 5510-5516

Also Published As

Publication number Publication date
JP2022514116A (ja) 2022-02-09
CN112867501A (zh) 2021-05-28
WO2020079448A1 (en) 2020-04-23
US20210353729A1 (en) 2021-11-18
CN112867501B (zh) 2025-01-07
AU2019360427A1 (en) 2021-03-18
CN119978090A (zh) 2025-05-13
JP2025041678A (ja) 2025-03-26
CA3112427A1 (en) 2020-04-23
JP7762132B2 (ja) 2025-10-29
US12263216B2 (en) 2025-04-01
EA202191081A1 (ru) 2021-07-09
KR20210080372A (ko) 2021-06-30
IL282308A (en) 2021-05-31
BR112021006941A2 (pt) 2021-08-31
EP3866827A1 (en) 2021-08-25
JP2023017853A (ja) 2023-02-07
MX2021004453A (es) 2021-09-10
WO2020079448A9 (en) 2020-05-22
US20250360206A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
JP7762132B2 (ja) 新規な癌抗原及び方法
JP2025032114A (ja) 新規な癌抗原及び方法
JP7751817B2 (ja) 新規な癌抗原及び方法
US20220211760A1 (en) Novel cancer antigens and methods
US20220220175A1 (en) Novel cancer antigens and methods
EP4136096A1 (en) Antigen pool

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250710

R150 Certificate of patent or registration of utility model

Ref document number: 7712207

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150